Ratings The Oncology Institute, Inc.

Equities

TOI

US68236X1000

End-of-day quote Nasdaq 06:00:00 2024-05-22 pm EDT 5-day change 1st Jan Change
0.55 USD -3.53% Intraday chart for The Oncology Institute, Inc. -13.93% -73.04%

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-73.04% 40.94M - -
+17.74% 82.59B
C+
-29.66% 69.86B
B-
0.00% 26.5B
C+
+3.06% 17.29B
A-
-12.16% 16.61B
B
+2.47% 15.56B
A-
+74.82% 13.2B
C-
+0.76% 12.75B
B-
+73.52% 12.6B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. TOI Stock
  4. Ratings The Oncology Institute, Inc.